Literature DB >> 7751163

Grouping HLA-B locus serologic specificities according to shared structural motifs suggests that different peptide-anchoring pockets may have contrasting influences on the course of HIV-1 infection.

S Itescu1, S Rose, E Dwyer, R Winchester.   

Abstract

Two different groups of HLA-B specificities were associated with two contrasting outcomes of HIV-1 infection. HLA-B45, -B49, and -B50 were each found at a moderately increased frequency among individuals responding to HIV-1 infection with a marked circulating and infiltrative CD8 T-cell lymphocytosis, a slow rate of CD4 T-cell decline, very low frequency of opportunistic infections, and low viral strain heterogeneity. In contrast, among HIV-infected individuals with more rapid progression to opportunistic infections, HLA-B35 was found to be increased in frequency and to act as a dominant marker for this adverse outcome. HLA-B45, -B49, and -B50 contain identical peptide-anchoring "B" and "C-terminal" pocket structures, which differ greatly from those present in HLA-B35, implying that different immunogenic peptides are likely to be bound by these two groups of alleles. Placing HLA-B45, -B49, and -B50 into one structurally defined group revealed a much stronger and statistically significant association with the CD8 lymphocytosis syndrome (OR = 5.3, p = 0.0005). The B pocket structure in these alleles contains an easily accessible lysine residue at position 45, suggesting that the P2 or P3 anchor residue of a bound peptide is negatively charged. Additionally, by observing the effect on the ORs of adding structures containing amino acid substitutions in the C-terminal pocket of HLA-B45, -B49, and -B50, this region was also shown to influence susceptibility to this host response.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7751163     DOI: 10.1016/0198-8859(94)00081-z

Source DB:  PubMed          Journal:  Hum Immunol        ISSN: 0198-8859            Impact factor:   2.850


  6 in total

1.  Motif of HLA-B*3503 peptide ligands.

Authors:  A Steinle; K Falk; O Rötzschke; V Gnau; S Stevanović; G Jung; D J Schendel; H G Rammensee
Journal:  Immunogenetics       Date:  1996       Impact factor: 2.846

2.  HLA-B35 upregulates endothelin-1 and downregulates endothelial nitric oxide synthase via endoplasmic reticulum stress response in endothelial cells.

Authors:  Stefania Lenna; Danyelle M Townsend; Filemon K Tan; Bagrat Kapanadze; Malgorzata Markiewicz; Maria Trojanowska; Raffaella Scorza
Journal:  J Immunol       Date:  2010-03-24       Impact factor: 5.422

3.  Major histocompatibility complex class II DR alleles DRB1*1501 and those encoding HLA-DR13 are preferentially associated with a diminution in maternally transmitted human immunodeficiency virus 1 infection in different ethnic groups: determination by an automated sequence-based typing method.

Authors:  R Winchester; Y Chen; S Rose; J Selby; W Borkowsky
Journal:  Proc Natl Acad Sci U S A       Date:  1995-12-19       Impact factor: 11.205

4.  Patterns of immunodominance in HIV-1-specific cytotoxic T lymphocyte responses in two human histocompatibility leukocyte antigens (HLA)-identical siblings with HLA-A*0201 are influenced by epitope mutation.

Authors:  P J Goulder; A K Sewell; D G Lalloo; D A Price; J A Whelan; J Evans; G P Taylor; G Luzzi; P Giangrande; R E Phillips; A J McMichael
Journal:  J Exp Med       Date:  1997-04-21       Impact factor: 14.307

Review 5.  Contribution of HIV Infection, AIDS, and Antiretroviral Therapy to Exocrine Pathogenesis in Salivary and Lacrimal Glands.

Authors:  Imran Nizamuddin; Peter Koulen; Carole P McArthur
Journal:  Int J Mol Sci       Date:  2018-09-13       Impact factor: 5.923

6.  Toxoplasmic encephalitis: role of Human Leucocyte Antigens/alleles associated with rapid progression to Acquired Immunodeficiency Syndrome.

Authors:  Maria de Lourdes Rodrigues; Neifi Hassam Deghaide; José Fernando Figueiredo; Marcelo Bezerra de Menezes; Ana Lúcia Demarco; Eduardo Donadi; Ana Paula Fernandes
Journal:  Braz J Infect Dis       Date:  2016-01-16       Impact factor: 3.257

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.